Digital Content 
NEWS #PharmaBuzz
08 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/atossa-therapeutics-announces-regulatory-strategy-aimed-at-accelerating-development-of-low-dose-z-endoxifen-for-breast-cancer-risk-reduction-302548910.html
20 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/atossa-therapeutics-selects-psi-as-contract-research-organization-for-pivotal-dose-ranging-study-of-z-endoxifen-in-metastatic-breast-cancer-302534234.html
14 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/atossa-therapeutics-announces-full-results-from-ispy-2-endocrineoptimization-substudy-evaluating-lowdose-zendoxifen-302455086.html
28 Jun 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/atossa-therapeutics-and-quantum-leap-healthcare-provide-enrollment-update-for-z-endoxifen-arm-of-ongoing-i-spy-2-clinical-trial-301865328.html
09 Jun 2021
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2021/06/09/2244416/0/en/Atossa-Therapeutics-Announces-Final-Data-from-Phase-2-Endoxifen-Breast-Cancer-Study-Primary-Endpoint-Met-65-1-Reduction-in-Biomarker-Ki-67-Secondary-Endpoint-Met-Endoxifen-Safe-and.html
30 Jul 2020
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2020/07/30/2070456/0/en/Atossa-Therapeutics-Announces-Findings-from-FDA-Approved-Expanded-Access-Treatment-with-Endoxifen.html
Share 